Aduhelm (aducanumab), first new Alzheimer’s drug in 20 years.
Aduhelm (aducanumab) has been approved by the FDA for the treatment of Alzheimer’s, a debilitating disease affecting 6.2 million Americans. Aduhelm was approved using the accelerated
We are a Swiss pharmaceutical wholesaler, specialized in sourcing and delivering pharma products, medical devices and drugs from and to all over the world.
Aduhelm (aducanumab) has been approved by the FDA for the treatment of Alzheimer’s, a debilitating disease affecting 6.2 million Americans. Aduhelm was approved using the accelerated
Vicolo Oldelli 1
6830 Chiasso / Switzerland
Email info@elixi-int.com
Phone/Fax +41 91 6822040
Copyright 2022 ELIXI International SA. | All Rights Reserved | Privacy Policy | Cookie Policy